Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — Q3 FY23 Earnings Presentation
12 slides from Jagsonpal Pharmaceuticals's earnings presentation, December 2023
Slide 1: Jagsonpal Pharmaceuticals Limited Q3 FY23 Earnings Presentation
Jagsonpal Pharmaceuticals Limited Q3 FY23 Earnings Presentation
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 3: Company Background
JAGSONPAL| Company Background
Slide 4: Company Snapshot
Company Snapshot Proven Track Record • Established in 1978, long track record of 40+ years Focus Segments • Specialize in the development & commercialisation of Gynaecology & Orthopaedic focussed products Strong Brands • 17 Brands are among the “Top 5” brands in respective molecule segments Extensiv
Slide 5: Q3 Performance
JAGSONPAL| Q3 Performance
Slide 6: Management Commentary
Management Commentary “Our performance in the current quarter continues to reflect the strong brand equity and business model of Jagsonpal in India. Our focus on key brands has resulted in 11.6% growth in sales which should further accelerate going forward. Improved product mix and strong control on
Slide 7: Q3 FY23 – Ground-work for profitable growth
Q3 FY23 – Ground-work for profitable growth Business • Continuing outperformance of domestic pharmaceutical industry (Source: IQVIA) on MAT December basis • Growth of 12.8% vis-à-vis industry growth of 6.5% • Improved industry ranking by 8 positions - 89th to 81st • Strong performance by Dydrogester
Slide 8: Key Brands – Yearly Progression basis MAT December
Key Brands – Yearly Progression basis MAT December MAT Dec’22 MAT Dec’21 MAT Dec’22 MAT Dec’21 Rank Rank Molecule Brand Sales Sales Market Share Market Share MAT Dec’22 MAT Dec’21 Hydroxyprogesterone Maintane Inj. 38.64 31.44 25.5% 24.9% 2 2 Allyelstrenol Maintane Tabs 17.77 17.62 52.7% 53.1% 1 1 Ly
Slide 9: Financial Performance
JAGSONPAL| Financial Performance
Slide 10: Profit and Loss Statement
Profit and Loss Statement All values in ₹ lakhs Q3 FY 23 Q2 FY 23 Q3 FY 22 YTD Dec’22 YTD Dec’21 Particulars Unaudited Unaudited Unaudited Unaudited Unaudited Revenue from Operations 6,014 6,053 5,391 18,126 16,636 Other Income 174 112 195 292 306 Total Income 6,188 6,165 5,586 18,418 16,942 Materia
Slide 11: Key Balance Sheet Items
Key Balance Sheet Items All value in ₹ lakhs st th As on 31 As on 30 Particulars December September Shareholders Funds 15,029 13,811 Tangible Assets 1,835 1,869 Cash and cash equivalents 10,083 8,400 Net Working Capital 2,686 3,247 11
Slide 12: Thank You
JAGSONPAL| Thank You
Jagsonpal Pharmaceuticals — Q3 FY23 Earnings Presentation on 6ix